Evidence map›Paper›PMID 36191034›Full record

ArticlePLoS pathogens2022

Revisiting Leishmania GP63 host cell targets reveals a limited spectrum of substrates.

Marie-Michèle Guay-Vincent, Christine Matte, Anne-Marie Berthiaume, Martin Olivier, Maritza Jaramillo, Albert Descoteaux

Open access · goldAbstract read
In one paragraph

Article in PLoS pathogens, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
6.8field-weighted citation impact, top 2% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 38 citations in OpenAlex.

  1. Frontiers in immunology · 2026
    Review
  2. Article
  3. Article
  4. Immunomodulatory properties ofFrontiers in parasitology · 2024
    Article
  5. Article
  6. LeishMANIAdb: a comparative resource for Leishmania proteins.Database : the journal of biological databases and curation · 2023
    Article
  7. Review
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Marie-Michèle Guay-VincentInstitut national de la recherche scientifique, Centre Armand-Frappier Santé Biotechnologie, Laval, Quebec, Canada.
Christine MatteInstitut national de la recherche scientifique, Centre Armand-Frappier Santé Biotechnologie, Laval, Quebec, Canada.
Anne-Marie BerthiaumeInstitut national de la recherche scientifique, Centre Armand-Frappier Santé Biotechnologie, Laval, Quebec, Canada.
Martin OlivierDepartment of Microbiology and Immunology, McGill University, Montréal, Quebec, Canada.
Maritza JaramilloInstitut national de la recherche scientifique, Centre Armand-Frappier Santé Biotechnologie, Laval, Quebec, Canada.
Albert DescoteauxInstitut national de la recherche scientifique, Centre Armand-Frappier Santé Biotechnologie, Laval, Quebec, Canada.ORCID 0000-0002-0633-5309
Institut National de la Recherche Scientifique · CAMcGill University Health Centre · CA

Funding

CIHR PJT-156416
6 · The paper itself

Abstract

Colonization of host phagocytic cells by Leishmania metacyclic promastigotes involves several parasite effectors, including the zinc-dependent metalloprotease GP63. The major mode of action of this virulence factor entails the cleavage/degradation of host cell proteins. Given the potent proteolytic activity of GP63, identification of its substrates requires the adequate preparation of cell lysates to prevent artefactual degradation during cell processing. In the present study, we re-examined the cleavage/degradation of reported GP63 substrates when GP63 activity was efficiently neutralized during the preparation of cell lysates. To this end, we infected bone marrow-derived macrophages with either wild type, Δgp63, and Δgp63+GP63 L. major metacyclic promastigotes for various time points. We prepared cell lysates in the absence or presence of the zinc-metalloprotease inhibitor 1,10-phenanthroline and examined the levels and integrity of ten previously reported host cell GP63 substrates. Inhibition of GP63 activity with 1,10-phenanthroline during the processing of macrophages prevented the cleavage/degradation of several previously described GP63 targets, including PTP-PEST, mTOR, p65RelA, c-Jun, VAMP3, and NLRP3. Conversely, we confirmed that SHP-1, Synaptotagmin XI, VAMP8, and Syntaxin-5 are bona fide GP63 substrates. These results point to the importance of efficiently inhibiting GP63 activity during the preparation of Leishmania-infected host cell lysates. In addition, our results indicate that the role of GP63 in Leishmania pathogenesis must be re-evaluated.

Indexed as

LeishmaniaProtein Tyrosine Phosphatase, Non-Receptor Type 12MetalloendopeptidasesMetalloproteasesNLR Family, Pyrin Domain-Containing 3 ProteinQa-SNARE ProteinsSynaptotagminsTOR Serine-Threonine KinasesVesicle-Associated Membrane Protein 3Virulence FactorsZincglycoprotein gp63, LeishmaniaMetalloendopeptidasesMetalloproteasesNLR Family, Pyrin Domain-Containing 3 ProteinProtein Tyrosine Phosphatase, Non-Receptor Type 12Qa-SNARE ProteinsSynaptotagminsTOR Serine-Threonine KinasesVesicle-Associated Membrane Protein 3Virulence FactorsZinc

Identifiers

PMID36191034
PMCPMC9560592
OpenAlexW4300688782

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.